# Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment

> **NCT05405270** · — · RECRUITING · sponsor: **Catharina Ziekenhuis Eindhoven** · enrollment: 410 (estimated)

## Conditions studied

- Cervical High Grade Squamous Intraepithelial Lesion
- Cervical Intraepithelial Neoplasia Grade 2/3
- CIN 2/3
- Cervical Intraepithelial Neoplasia

## Interventions

- **DRUG:** Imiquimod
- **DIAGNOSTIC_TEST:** 3x vaginal swab for microbiome analysis
- **OTHER:** Expectative management
- **DIAGNOSTIC_TEST:** 2x vaginal swab for microbiome analysis

## Key facts

- **NCT ID:** NCT05405270
- **Lead sponsor:** Catharina Ziekenhuis Eindhoven
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-01
- **Primary completion:** 2024-12
- **Final completion:** 2026-12
- **Target enrollment:** 410 (ESTIMATED)
- **Last updated:** 2023-09-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05405270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05405270, "Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05405270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*